Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Heptares Therapeutics Limited - Product Pipeline Review - 2016 Summary
Global Markets Direct's, 'Heptares Therapeutics Limited - Product Pipeline Review - 2016', provides an overview of the Heptares Therapeutics Limited's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Heptares Therapeutics Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Heptares Therapeutics Limited - The report provides overview of Heptares Therapeutics Limited including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Heptares Therapeutics Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Heptares Therapeutics Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to buy
- Evaluate Heptares Therapeutics Limited's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Heptares Therapeutics Limited - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Heptares Therapeutics Limited's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Heptares Therapeutics Limited Snapshot 6 Heptares Therapeutics Limited Overview 6 Key Information 6 Key Facts 6 Heptares Therapeutics Limited - Research and Development Overview 7 Key Therapeutic Areas 7 Heptares Therapeutics Limited - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Heptares Therapeutics Limited - Pipeline Products Glance 14 Heptares Therapeutics Limited - Clinical Stage Pipeline Products 14 Phase I Products/Combination Treatment Modalities 14 Heptares Therapeutics Limited - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Heptares Therapeutics Limited - Drug Profiles 17 HTL-9936 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 HTL-1071 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 HTL-14242 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 HTL-6641 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule to Agonize GPR39 for Type 1 and Type 2 Diabetes 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibody to Antagonize GPCR for Inflammation 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibody to Target GPCR for Undisclosed Indications 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecule to Antagonize CXCR4 for Cancer and HIV 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecule to Target GPCR for CNS Disorders 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecule to Target mGluR2 for Schizophrenia 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Small Molecules to Target GPCR for Pain, Cardiovascular, Metabolic and Inflammatory Disorders 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Heptares Therapeutics Limited - Pipeline Analysis 33 Heptares Therapeutics Limited - Pipeline Products by Target 33 Heptares Therapeutics Limited - Pipeline Products by Route of Administration 34 Heptares Therapeutics Limited - Pipeline Products by Molecule Type 35 Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action 36 Heptares Therapeutics Limited - Recent Pipeline Updates 37 Heptares Therapeutics Limited - Dormant Projects 42 Heptares Therapeutics Limited - Locations And Subsidiaries 43 Head Office 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Heptares Therapeutics Limited, Key Information 6 Heptares Therapeutics Limited, Key Facts 6 Heptares Therapeutics Limited - Pipeline by Indication, 2016 8 Heptares Therapeutics Limited - Pipeline by Stage of Development, 2016 10 Heptares Therapeutics Limited - Monotherapy Products in Pipeline, 2016 11 Heptares Therapeutics Limited - Out-Licensed Products in Pipeline, 2016 12 Heptares Therapeutics Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016 13 Heptares Therapeutics Limited - Phase I, 2016 14 Heptares Therapeutics Limited - Preclinical, 2016 15 Heptares Therapeutics Limited - Discovery, 2016 16 Heptares Therapeutics Limited - Pipeline by Target, 2016 33 Heptares Therapeutics Limited - Pipeline by Route of Administration, 2016 34 Heptares Therapeutics Limited - Pipeline by Molecule Type, 2016 35 Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action, 2016 36 Heptares Therapeutics Limited - Recent Pipeline Updates, 2016 37 Heptares Therapeutics Limited - Dormant Developmental Projects,2016 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
